Phosphoinositide-3-kinase (PI3K) plays an important role in the EGFR signaling pathway. The gene, PIK3CA, encoding the catalytic subunit of PI3K, has been found to be frequently mutated in human cancers including colon cancer, gliomas, gastric cancer, breast cancer, endometrial cancer, and lung cancer1,2. PIK3CA mutations in cancer cells are associated with early recurrence, poor prognosis and drug resistance. Analysis of PIK3CA mutations has been shown to be valuable in optimizing the anti-EGFR therapies for different types of cancers like lung cancer and metastatic colorectal cancers3-5.
Based on Shifted Termination Assay (STA) technology, MutectorTM reagents contain special chemistry and a modified enzyme mixture to enrich the mutation signal 20-fold and detect as low as 1% mutation in wild type background. MutectorTM reagents have been widely used to detect BRAF, KRAS and other mutations such as PIK3CA in clinical samples including FFPE samples (see STA/Mutector-related Publications).
The difference:
- Single tube detects mutations in two exons – Simultaneously detect 5 mutations (see below), detects all possible mutations in target codon
- Use less clinical samples – works for small samples such as fine needle aspiration (FNA)
- Detects low level (1-5%) mutations
- Accurate – sequencing-like accuracy, the mutation is double confirmed by peak color and fragment size
Assay Information
Assay Format One tube test
Target Mutations Exon 9: E542K, F545G, E545K
Exon20: H1047L, H1047R
Assay Platform Capillary sequencer ABI 3100, 3700, 3130, 3500
Assay Sensitivity Detects 1-2% PIK3CA mutations
Sample required 20-160 ng DNA
Assay workflow
Sensitivity
Use 20 - 160ng DNA per reaction. These reagents detect 1-2% mutation(s) of total DNA and detect some mutations that are missed by sequencing
Order Information
| Cat. No. | Product Name | Target Mutations | Size | Documents |
| Cor-A | STA Core Reagents A | Universal Reagents for Point Mutations | 32 rxn | Protocol |
The gene specific primers are not included in the kit. For research use only. Not for use in diagnostic procedures.
Core: Cor-A
DNA Primer: DP08
Data:
The MutectorTM assay can simultaneously detect 5 PIK3CA mutations in the same tube:
Related Products
- FFPE Sample DNA Extraction– high yield DNA in 1 hour, 99% PCR success rate
- Mutation Analysis Reagents for Oncology – single platform for any somatic mutations
- Mutation Analysis Reagents for Pharmacogenetics – single platform for any genotyping
References
- Samuels Y et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:554
- Karakas B et al. (2006). Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 94:455
- Ligresti G et al. (2009). PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle. 8:1352
- De Roock W et al. (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594.
- Sequist LV et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra26